BridgeBio Pharma, Inc. 8-K

What Happened
BridgeBio Pharma (BBIO) announced a financing on July 1, 2026 and filed an 8‑K on July 2, 2026: it sold 933,900 shares of newly created Series A Cumulative Convertible Participating Preferred Stock for a total of $933.9 million. Purchasers include Chinotto Investments, LLC (the Sixth Street purchaser) and HCRx Investments HoldCo, L.P. (the HCR purchaser, affiliated with KKR and connected to board member Ali Satvat). The company also entered a Registration Rights Agreement to register resale of common shares issuable on conversion.

Key Details

• Purchase amount and buyers: 933,900 preferred shares at $1,000 each = $933,900,000 total (800,000 shares / $800.0M to Sixth Street; 133,900 shares / $133.9M to HCRx). Sixth Street may provide up to an additional $66.1M (subject to board approval) on substantially identical terms.
• Conversion and voting: Initial conversion price $137.79 per share (subject to adjustment); conversion price becomes $153.10 on/after the 5th anniversary. Holders vote with common stock on an as-converted basis; holders also have separate consent rights on certain corporate actions.
• Dividends and seniority: Preferred accrues a 7.00% annual dividend (compounded or cash, payable quarterly), with mechanisms that can raise the rate over time (including step-ups and caps up to 17%). Preferred ranks senior to common stock for dividends and liquidation.
• Limits, redemption and approvals: Beneficial ownership conversion limit of 19.9% applies until the company seeks stockholder approval (to be sought at the 2027 annual meeting or by special meeting no later than June 30, 2027). Company may force conversion or redeem under certain conditions after multi‑year thresholds; change‑of‑control purchase and other protections are included.

Why It Matters
This is a major capital raise ($933.9M) that provides BridgeBio with substantial non-dilutive cash upfront relative to issuing common shares, but it introduces a new senior preferred security with dividend obligations and conversion terms that can affect future dilution and capital structure. Investors should note the conversion price, the 19.9% beneficial ownership cap until shareholder approval in 2027, the sizable dividend and potential step-ups, and Sixth Street’s option to invest more — all of which can influence future dilution, cash dividend requirements, and takeover/transaction outcomes. The company also agreed to file a shelf registration for the common shares issuable upon conversion, enabling future resale by the preferred holders.